$0.38
15.98% day before yesterday
Nasdaq, Dec 27, 10:07 pm CET
ISIN
US1407551092
Symbol
CARA
Sector
Industry

Cara Therapeutics Inc Stock price

$0.38
+0.09 31.20% 1M
+0.07 24.14% 6M
-0.37 49.13% YTD
-0.28 42.74% 1Y
-12.19 96.99% 3Y
-16.23 97.72% 5Y
-9.57 96.20% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.07 15.98%
ISIN
US1407551092
Symbol
CARA
Sector
Industry

Key metrics

Market capitalization $20.74m
Enterprise Value $21.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.44
P/S ratio (TTM) P/S ratio 2.39
P/B ratio (TTM) P/B ratio 29.33
Revenue growth (TTM) Revenue growth -59.08%
Revenue (TTM) Revenue $8.69m
EBIT (operating result TTM) EBIT $-82.39m
Free Cash Flow (TTM) Free Cash Flow $-77.34m
Cash position $43.54m
EPS (TTM) EPS $-1.75
P/E forward negative
P/S forward 2.37
EV/Sales forward 1.05
Short interest 2.00%
Show more

Is Cara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Cara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Cara Therapeutics Inc forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Cara Therapeutics Inc forecast:

Buy
20%
Hold
80%

Financial data from Cara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.69 8.69
59% 59%
100%
- Direct Costs 1.50 1.50
81% 81%
17%
7.18 7.18
46% 46%
83%
- Selling and Administrative Expenses 28 28
10% 10%
326%
- Research and Development Expense 61 61
42% 42%
701%
-82 -82
31% 31%
-945%
- Depreciation and Amortization 0.27 0.27
85% 85%
3%
EBIT (Operating Income) EBIT -82 -82
31% 31%
-948%
Net Profit -96 -96
18% 18%
-1,099%

In millions USD.

Don't miss a Thing! We will send you all news about Cara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cara Therapeutics Inc Stock News

Neutral
GlobeNewsWire
2 days ago
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.
Neutral
Business Wire
11 days ago
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Cara (NASDAQ: CARA) for possible breaches of fiduciary duty and other violations of law in its transaction with Tvardi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, pre-Merger Car...
Neutral
GlobeNewsWire
11 days ago
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases

Company Profile

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

Head office United States
CEO Christopher Posner
Employees 55
Founded 2004
Website www.caratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today